17-hydroxiprogesterone values in healthy preterm infants
Abstract
Introduction:In preterm newborn, problems with the interpretation of 17-OHP may occur.
Objective:Evaluate 17-OHP values in healthy preterm newborns until they reach the corrected gestational age.
Methods:Longitudinal study of 36 preterm infants with 17-OHP evaluation using ELISA from heel blood from 3 to 5 days and thereafter every 2 weeks until the corrected gestational age. Values adjusting multiple variables such as gestational age, birth weight and sex, among others were compared. The results were analyzed against 82 healthy full-term infants.
Results:In the first week of life, early term infants born within less than 34 months of gestational age show 17-OHP values that are much higher than the full term neonates. After a week, the values decrease and stabilize, but are still higher than those of full term neonates and remain so even at the corrected gestational age. (average difference of 63.0%, IC 95%: 11.8%-115.5%). 33.6% (41 samples) of a total of 122 samples taken from preterm infants were higher than 30 ng/mL.
Conclusions:17-OHP values in early term infants are higher than those in full term neonates and can be related to postnatal adaptive processes. It is suggested that a second screening at the 37th week of corrected age be performed.
Authors
Downloads
Keywords
- Neonatal screening
- 17-alpha-Hidroxiprogesterone
- Adrenal Hyperplasia Congenital
References
Pang S, Wallace M, Hofman L, Thuline H, Dorche C, Lyon I, et al. Worldwide experience in newborn screening for classical congenital adrenal hyperplasia due to 21-hydroxilase deficiency. Pediatrics. 1988; 81:866-74.
Montoya-Tamayo C, Román-González A, Zapata-Garcés J, Manuel J, Velásquez A. Caracterización clínica y epidemiológica de una cohorte de pacientes con hiperplasia adrenal. Medicina y Laboratorio. 2007; 19:451-60.
Speiser PW, Azziz R, Baskin LS, Ghizzoni L, Hensle TW, Merke DP, et al. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010; 95:4133-60.
Rey T, García A. El cribado neonatal de la hiperplasia adrenal congénita: una revisión sistemática. Endocrinol Nutr. 2007; 54: 216-24.
Rey T, García A. Cribado neonatal de la hiperplasia adrenal congénita. Aplicabilidad en Galicia. Santiago de Compostela: Servicio Galego de Saúde, Axencia de Avaliación de Tecnoloxías Sanitarias de Galicia, avalia-t; 2004. Serie Avaliación de Tecnoloxías. Informes; INF2004/03.
Hayashi G, Faure C, Brondi MF, Vallejos C, Soares D, Oliveira E, et al. Weight-adjusted neonatal 17OH-progesterone cutoff levels improve the efficiency of newborn screening for congenital adrenal hyperplasia. Arq Bras Endocrinol Metabol. 2011; 55: 632-7.
Allen DB, Hoffman GL, Fitzpatrick P, Laessig R, Maby S, Slyper A. Improved precision of newborn screening for congenital adrenal hyperplasia using weight-adjusted criteria for 17-hydroxyprogesterone levels. J Pediatr. 1997; 130: 128-33.
Cattani A, Loreto-Reyes M, Azócar M. Medición de 17-OH progesterona sanguínea en recién nacidos chilenos: Antecedentes para implementar un programa de detección neonatal de hiperplasia adrenal congénita. Rev Med Chile. 2000; 128: 1113-8.
Coto R, Varona J, Borrego J, Formoso L. Resultados de la pesquisa de hiperplasia adrenal congénita en recién nacidos. Rev Cub Obstet Ginecol. 2011; 37: 1-10.
Ryckman KK, Cook DE, Berberich SL, Shchelochkov OA, Berends SK, Busch T, et al. Replication of clinical associations with 17-hydroxyprogesterone in preterm newborns. J Pediatr Endocrinol Metab. 2012; 25: 301-5.
Cavarzere P, Samara-Boustani D, Flechtner I, Dechaux M, Elie C, Tardy V, et al. Transient hyper-17-hydroxyprogesteronemia: a clinical subgroup of patients diagnosed at neonatal screening for congenital adrenal hyperplasia. Eur J Endocrinol. 2009; 161: 285-92.
Chennuri V, Mithbawkar S, Mokal R, Desai M. Serum 17 alpha hydroxyprogesterone in normal full term and preterm vs sick preterm and full term newborns in a tertiary hospital. Indian J. Pediatr. 2013; 80: 21-5.
Ballerini M, Chiesa A, Scaglia P, Gruñeiro-Papendieck L, Heinrich J, Ropelato M. 17 Alpha-Hydroxyprogesterone and cortisol serum levels in neonates and young children: Influence of age, gestational age, gender and methodological procedures. J Pediatr. Endocrinol. Metab. 2010; 23: 121-32.
Fenton T, Kim J. A systematic review and meta-analysis to revise the Fenton growth chart for preterm infants. BMC Pediatr. 2013; 13: 1-13.
Monobid Inc, Neonatal 17aOH Progesterona (N-17OHP) Test System package insert. Código de product 5525-300; Julio 10, 2013. Available from: http://www.annardx.com/productos/images/productos/diagnostica/endocrinologia/5525300-f5-n17ohp -accubind -elisa-10072013-es475008746.pdf.
Rabe-Hesketh S, Skrondal A. Multilevel and longitudinal modeling using Stata. Volume II: Categorical responses, counts, and survival. 3 ed, College Station: Stata Press, 2012.
Al Saedi S, Dean H, Dent W, Stockl E, Cronin C. Screening for congenital adrenal hyperplasia: The Delfia screening test overestimates serum 17-hydroxyprogesterone in preterm infants. Pediatrics 1996; 97:100-2.
Linder N, Davidovitch N, Kogan A, Barzilai A, Kuint J, Mazkeret R, et al. Longitudinal measurements of 17alpha-hydroxyprogesterone in premature infants during the first three months of life. Arch. Dis. Child. Fetal Neonatal Ed. 1999; 81: F175-8.
Nordenstrom A, Wedell A, Hagenfeldt L, Marcus C, Larsson A. Neonatal screening for Congenital Adrenal Hyperplasia: 17-hydroxyprogesterone levels and CYP21 genotypes in preterm infants. Pediatrics. 2001; 108: e68.
Ishimoto H, Jaffe R. Development and function of the human fetal adrenal cortex: a key component in the feto-placental unit. Endocr Rev. 2011; 32: 317-55.
Huet F, Godefroy A, Cheillan D, Somma C, Roussey M. Faut-il mantenir un déspistage de l´hyperplasie congenital des surrénales pour les prématurés? Arch Pédiatrie. 2014; 21: 233-6.
Chung H. Adrenal and thyroid function in the fetus and preterm infant. Korean J Pediatr. 2014; 57: 425-33.
Van der Kamp H, Oudshoorn C, Elvers B, van Baarle M, Otten B, Wit J, et al. Cuttoff levels of 17-alfa hydroxyprogesterone in neonatal screening for congenital adrenal hyperplasia should be based on gestational age rather than on birth weight. J Clin Endocrinol Metab. 2005; 90: 3904-7.
Kaludjerovic J, Ward W. The interplay between estrogen and fetal adrenal cortex. J Nutr Metab. 2012: 837901.
Heckmann M, Hartmann M, Kampschulte B, Gack H, Bödeker R, Gortner L, et al. Persistent high activity of the fetal adrenal cortex in preterm infants: is there a clinical significance? J Pediatr Endocrinol Metab. 2006; 19: 1303-12.
Ministerio de Salud y Protección Social - Colciencias. Guía de práctica clínica. Guía No. 03: Detección de anomalías congénitas en el recién nacido. Colombia, 2013..
The copy rights of the articles published in Colombia Médica belong to the Universidad del Valle. The contents of the articles that appear in the Journal are exclusively the responsibility of the authors and do not necessarily reflect the opinions of the Editorial Committee of the Journal. It is allowed to reproduce the material published in Colombia Médica without prior authorization for non-commercial use
